1 Comparison of COVID-19 outcomes among shielded and non-shielded populations: 2 A general population cohort study of 1.3 million 3 4 5 6 Bhautesh D Jani,\* Frederick K Ho,\* David J Lowe, Sean MacBride-Stewart, Frances S Mair, 7 Jill P Pell 8 9 \*Joint-first author 10 11 Bhautesh D Jani PhD 12 Clinical Senior Lecturer in General Practice and Primary Care Institute of Health and Wellbeing, University of Glasgow, 13 14 Glasgow G12 9LX, UK 15 Bhautesh.jani@glasgow.ac.uk 16 17 Frederick K Ho PhD 18 Research Associate 19 Institute of Health and Wellbeing, University of Glasgow 20 Glasgow, G12 8RZ, UK 21 Frederick.Ho@glasgow.ac.uk 22 23 David J Lowe MSc 24 Consultant in Emergency Medicine, 25 Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, 26 Glasgow, G52 4TF, UK 27 David.lowe@nhs.net 28 29 Sean MacBride-Stewart PhD 30 Lead Pharmacist (Medicines Management Resources) 31 **Pharmacy Services** 32 NHS Greater Glasgow and Clyde, G76 7AT, UK Sean.MacBride-Stewart@ggc.scot.nhs.uk 33 34 Frances S Mair MD 35 36 Norie Miller Professor of General Practice 37 Institute of Health and Wellbeing, University of Glasgow, 38 Glasgow G12 9LX, UK 39 Frances.mair@glasgow.ac.uk 40 41 Jill P Pell MD 42 Henry Mechan Professor of Public Health 43 Institute of Health and Wellbeing, University of Glasgow, 44 Glasgow, G12 8RZ, UK 45 Jill.pell@glasgow.ac.uk 46

**Address for correspondence:** Professor Jill Pell Director of the Institute of Health and Wellbeing University of Glasgow 1 Lilybank Gardens Glasgow G12 8RZ United Kingdom Jill.pell@glasgow.ac.uk Abstract word count Main text word count 3,317 **Tables** Supplementary Tables Supplementary Figures Number of references 

## **Abstract**

1

- 2 Background
- 3 Shielding (extended self-isolation) of people judged, a priori, to be at high-risk from COVID-
- 4 19 has been used by some countries to protect the individuals and reduce demand on health
- 5 services. It is unclear how well this strategy works in either regard.
- 6 Methods
- A general population study was conducted using linked primary care, prescribing, laboratory,
- 8 hospital and death records up to end of May 2020. Poisson regression models and population
- 9 attributable fractions were used to compare COVID-19 outcomes by overall risk category,
- and individual risk criteria: confirmed infection, hospitalisation, intensive care unit (ICU)
- admission, population mortality and case-fatality.
- 12 Results
- Of the 1.3 million population, 32,533 (2.47%) had been advised to shield, a further 347,374
- 14 (26.41%) were classified as moderate risk. Testing for COVID-19 was more common in the
- shielded (6.75%) and moderate (1.99%) than low (0.72%) risk categories. Referent to low-
- risk, the shielded group had higher risk of confirmed infection (RR 7.91, 95% 7.01-8.92),
- 17 case-fatality (RR 5.19, 95% CI 4.12-6.53) and population mortality (RR 48.64, 95% 37.23-
- 18 63.56). The moderate risk had intermediate risk of confirmed infection (RR 4.11, 95% CI
- 19 3.82-4.42) and population mortality (RR 26.10, 95% CI 20.89-32.60), but had comparable
- 20 case-fatality (RR 5.13, 95% CI 4.24-6.21) to the shielded, and accounted for a higher
- 21 proportion of deaths (PAF 75.27% vs 13.38%). Age ≥70 years made the largest contribution
- 22 to deaths (49.53%) and was associated with an 8-fold risk of infection, 7-fold case-fatality
- and 74-fold mortality.

## 24 Conclusions

- 1 Shielding has not been effective at preventing deaths in those with highest risk. To be
- 2 effective as a population strategy, shielding criteria would need to be widely expanded to
- 3 include other criteria, such as the elderly.
- 5 **Keywords (MeSH terms):**

4

7

8

6 Cohort studies; COVID-19; epidemiology; vulnerable populations

**Background** 

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Early in the COVID-19 pandemic, one of the greatest concerns was that the demand on health services would exceed capacity in terms of hospitalisations, admissions to intensive care units (ICU) and requirement for ventilation <sup>1</sup>. Based on past experience, it was assumed that sub-groups of the population would have worse prognosis and, therefore, contribute disproportionately to adverse outcomes and healthcare demands. Asian countries have generally relied solely on population-wide strategies<sup>2</sup>. Early, widespread 'test, trace, isolate' strategies were made possible by higher testing capacity and a greater willingness to monitor and enforce compliance. In contrast, European countries have generally adopted a two-pronged approach <sup>2</sup>, whereby general population interventions, such as physical distancing and hand hygiene, designed to reduce transmission in the population as a whole, have been supplemented by shielding of those assumed to be at higher risk. Notably, Sweden, an outlier in having not applied lock-down, nonetheless mandated shielding<sup>3</sup>. Studies suggest that shielding can have negative physical and psychological impact on those required to undertake strict isolation over a protracted period.<sup>4,5</sup> In the United Kingdom, a Shielded Patient List (initially referred to as the Vulnerable Patient List) was produced comprising two categories (Supplementary Table 1)<sup>6</sup>. The two groups have been labelled high risk, highest risk or clinically extremely vulnerable and moderate risk, at risk or clinically vulnerable by various UK organisations. For the purposes of this study they are referred to as shielded and moderate risk, with the remaining population labelled low risk. In the United Kingdom, the shielded group received individual letters strongly recommending that they self-isolate over a protracted period, by not leaving their

homes and avoiding non-essential contact with their household members, and were provided with support at home such as the delivery of food packages. The advice to the moderate risk category was simply to be vigilant in adhering to the general population measures. The definitions of high and moderate risk were based largely on expert opinion informed by our understanding of previous viruses and the critical need for better definition of high risk has been highlighted <sup>7</sup>. Studies are emerging of the individual risk factors associated with COVID-19 outcomes. For example, among two million UK community-based app users selfreported heart disease, kidney disease, lung disease, diabetes and obesity were associated with self-reported hospital admission and respiratory support for COVID-19 8. Similarly, linkage of primary care records of 17 million people in England demonstrated that a wide range of long-term conditions were associated with in-hospital death from COVID-19 including: respiratory, heart, liver and kidney disease, diabetes, cancers, stroke and organ transplantation <sup>9</sup>. Unfortunately, the investigators did not have access to deaths in the community. COVID-19 risk scores are being developed in an attempt to improve identification of high risk individuals who would be advised to shield <sup>10</sup> but attempts to investigate the potential contribution of a shielding strategy to population-level outcomes and healthcare demands have so far been limited to abstract mathematical modelling 11-19. The aims of this study were to compare those classified, a priori, as high risk (and therefore advised to shield) and those classified as moderate and low risk, in terms of their individual risk of COVID-19 infection and outcomes and the extent to which they accounted for COVID-19 related outcomes at a population level.

# Methods

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

We conducted a general population cohort study of all 1.3 million residents of NHS Greater Glasgow and Clyde (NHS GGC) in Scotland. The Community Health Index (CHI), a unique identifier attached to all health records in Scotland, was used to undertake individual-level record linkage via exact matching of nine databases: Community Health Index (CHI) register, NHS GGC Shielding List, Egton Medical Information Systems (EMIS) and Vision, Electronic Communication of Surveillance in Scotland (ECOSS), Prescribing Information System (PIS), Rapid Preliminary Inpatient Data (RAPID), and death certificates. The CHI register provided sociodemographic information (age, sex, socioeconomic deprivation). Socioeconomic deprivation was derived from the Scottish Index of Multiple Deprivation (SIMD), an area-based measure derived from seven domains - income, education, health, employment, crime, housing, and access to services – which was categorised into general population quintiles. The Electronic Communication of Surveillance in Scotland (ECOSS) database collects laboratory data on infectious diseases, including test date and result. EMIS and Vision are the primary care electronic health record systems used in NHS GGC. Data are extracted using Albasoft software. The PIS collects data on all medications prescribed by community-based healthcare workers, including general practitioners. The RAPID database collects real-time data on every patient admitted to a general (i.e. non-psychiatric) hospital in Scotland including dates of admission and discharge, and type of ward (e.g. ICU) but does not record disease codes. Subsequently, the Scottish Morbidity Record 01 (SMR01) records the same information, in addition to disease codes. Death certificates provide the date and cause of death for all deaths, whether they occur in-

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

hospital or in the community. Follow-up data were available until the end of May 2020, before the recommendation to shield was lifted. Supplementary Table 1 lists the criteria for the shielded and medium risk categories being applied in the United Kingdom at the time of data extraction. All remaining patients are categorised as low risk. The Scottish list of high-risk individuals is compiled, and regularly updated, centrally using data obtained from a number of sources including Albasoft extraction of general practice data, SMR01 (hospital admissions), SMR06 (cancer registry), national disease registries, and the PIS. The list is sent to individual general practitioners to check for completeness and accuracy, before letters are sent to patients with advice to shield. The NHS GGC Shielding List contains the validated data including the criterion satisfied. We ascertained people who met the criteria for moderate risk via Albasoft extraction of EMIS and Vision data and PIS data. Separate models were conducted for two exposure variables: overall risk category (low, moderate or high) and the individual criteria for the moderate and high-risk categories. The four general population outcomes investigated were: confirmed COVID-19 infection; COVID-19 related hospitalisation; COVID-19 related ICU admission; COVID-19 related mortality. The three outcomes investigated among those with confirmed infection were; COVID-19 related hospitalisation; COVID-19 related ICU admission; and COVID-19 related case fatality. Laboratory-confirmed cases were defined as patients who had a positive PCR test for COVID-19. Clinically-confirmed cases were defined as patients who either had a positive PCR test or who died from COVID-19 without testing. COVID-related deaths were defined

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

as deaths with International Classification of Diseases 10<sup>th</sup> revision (ICD-10) code U07.1 or U07.2 recorded on the death certificate. COVID-related hospitalisation was defined as an SMR01 record of hospitalisation with an ICD code U07.1 or U07.2 or, for more recent admissions, a RAPID record of hospitalisation with a positive COVID-19 test taken between two weeks before and two days after admission to hospital. ICU admission during such hospitalisations was assumed to be COVID-related. The sociodemographic characteristics of people were compared by risk category using chisquare tests. Poisson regression models with robust standard errors were used to compare the risk ratios (RR) for the high and moderate risk categories referent to the low risk category for each outcome in turn. The models were run univariately and then adjusted for sex and SIMD quintiles as potential confounders. Age was not included as a covariate because it was a moderate risk criterion. The models were re-run using the individual criteria for the high and moderate risk categories as the exposure variables, referent to the low risk category. Population attributable fractions (PAFs) were calculated, from prevalence and adjusted RR, to determine the proportion of each outcome that could be attributed to being high and moderate risk, as well as the proportion due to each of the individual criteria. The PAFs of individual criteria were proportionally calibrated so that the sum of PAFs of individual criteria equated to the overall PAF of the relevant risk category. PAF confidence intervals were estimated using bootstrapping (x 1000). Ethical approvals

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

The study was approved by the NHS Greater Glasgow and Clyde Primary Care Information Sharing Group and the NHS Greater Glasgow and Clyde Local Privacy Advisory Committee (LPAC) (Reference GSH/20RM005) and was covered by the generic Safe Haven Research Ethics Committee approval (GSH20RM005\_COVID\_Community). **Results** Of the 1,315,071 people registered with general practitioners in NHS Greater Glasgow and Clyde, 32,533 (2.47%) were recorded as requiring shielding and 347,374 (26.41%) were classified, a priori, as being at moderate risk. Of the 32,533 people in the shielded group, 18,147 (55.78%) had severe respiratory disease, 6,761 (20.78%) were on renal dialysis, 5,349 (16.44%) were on immunosuppressive therapies, 2,491 (7.66%) had specific cancers, 1,245 (3.83%) had received organ transplants, and less than five were pregnant and had severe heart disease. Of the 347,374 people classified as moderate risk, 160,215 (46.12%) had hypertension, 151,865 (43.72%) had chronic lung disease, 139,568 (40.18%) were at least 70 years of age, 64,358 (18.53%) had diabetes, 48,571 (13.98%) had heart disease, and 1,195 (0.34%) had a weakened immune system. Shielded and moderate risk categories Overall, 15,865 (1.21%) people had been tested for COVID-19. The likelihood of having been tested increased with age, was higher in women and was higher in the moderate-risk category and highest in the shielded group (Table 1). Overall, 3,348 (0.25%) people had confirmed COVID-19 infection. The likelihood of laboratory-confirmed COVID-19 infection followed similar patterns as testing. It increased with age, was higher in women, and was

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

highest in the shielded group and lowest in the low-risk category (Table 2). After adjustment for sex and deprivation quintile, the risk of laboratory-confirmed infection remained higher in the moderate-risk category and highest in the shielded group (Table 3). Overall, 1,661 people were admitted to hospital for COVID-19. Within the general population, hospitalisations increased with age but were comparable between men and women (Table 2). Hospitalisations were more common in the moderate-risk category and most common in the shielded group (Table 2) and remained so after adjustment for sex and deprivation quintile (Table 3). Overall, 122 people were admitted to ICU wards for COVID-19. ICU admissions were significantly more common among people aged 45-64 years of age than among older people (Table 2). Compared with the low risk category, the shielded group were 18 times more likely to be hospitalised but only 4 times more likely to be admitted to ICU (Table 3). Overall, 1,027 (0.08%) people died from COVID-19. Within the general population, mortality increased with age but was similar in men and women (Table 2). Population mortality was higher in the moderate-risk category and highest in the shielded group (Table 2) and remained so after adjustment for sex and deprivation quintile (Table 3). Among the sub-group with laboratory-confirmed (test-positive) COVID-19 infection, 1,661 (49.6%) were hospitalised. Hospitalisations increased with age but were comparable between men and women (Table 4). The moderate-risk category was more likely to be hospitalised and the shielded group most likely (Table 4) and remained so after adjustment for age and deprivation quintile (Table 5). Among the sub-group with laboratory-confirmed COVID-19 infection, ICU admissions were more common in men and more common in people aged 45-64 years than those older (Table 4). Low risk cases were more likely to be admitted to ICU than those in the moderate-risk category and shielded groups (Tables 4 & 5). Among the sub-

1 group with clinically-confirmed (test-positive or COVID-19 related death) COVID-19

infection, 1,027 (26.70%) died (Table 4). Case-fatality increased by age and was higher in

men than women. It was lowest in the low-risk category but not significantly different in the

moderate-risk category and shielded group (p=0.64) (Table 5).

6 The shielded group accounted for 8.58% of laboratory-confirmed COVID-19 infections,

7 15.45% of COVID-19 hospitalisations, 4.91% of ICU admissions and 13.38% of COVID-19

related deaths (Supplementary Table 2). The corresponding figures for the moderate risk

category were 41.22%, 61.33%, 20.78% and 75.27%. To prevent at least 80% of deaths,

28.8% of the population would have had to receive the current level of shielding including

those with five criteria currently classified as moderate risk (Supplementary Figure 1).

## Individual risk criteria

Due to insufficient numbers, the models for individual risk criteria could not be run for pregnant women with severe heart disease or for COVID-19 related ICU admission in the high-risk category. All of the remaining individual risk criteria were associated with higher likelihood of being tested for COVID-19 (Table 1) and higher likelihood of having laboratory-confirmed infection (Table 2). They were all associated with higher risk of hospitalisation, population mortality (Table 3) and case-fatality (Table 5) independent of sex and deprivation quintile. Among the moderate-risk category criteria, age ≥70 years and weakened immune system had risks of population mortality (Table 3) and case-fatality (Table 5) that were at least as high as the overall shielded group. Apart from the 0.13% of people with relevant rare diseases and inborn errors of metabolism, the strongest associations were observed for those aged ≥70 years who were eight times more likely to have confirmed

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

infection (Table 3); seven times more likely to die following confirmation of infection (Table 5); and seventy four times as likely to die overall (Table 3) compared with those in low risk category. Being more than 70 years of age accounted for 17.45% of confirmed COVID-19 infections, 22.90% of COVID-19 related hospitalisations, and 49.53% of COVID-19 related deaths (Supplementary Table 2). Among those admitted to hospital for COVID-19, the likelihood of being admitted to ICU was significantly lower for all of the individual risk criteria included in the moderate risk category, other than diabetes (Table 5). In particular, hospitalised patients over 70 years of age were 14 times less likely to be admitted to ICU than low risk hospitalised patients (Table 5). **Discussion** The 2.47% of people who had been advised to shield were, nonetheless, eight times more likely to have confirmed infections than the low risk category, five times more likely to die following confirmed infection and 49 times more likely to die from covid-19 overall. Whilst selective testing of potential cases might explain the first outcome, it does not explain higher overall mortality which suggests that the shielding strategy has not been as effective as was hoped. One quarter of the population were classified as moderate risk and not advised to shield. Nonetheless, they were four times more likely to have confirmed infections than the low risk category, five times more likely to die following confirmed infection and 26 times more likely to die overall, suggesting that consideration should be given to expanding the shielding criteria to include many currently classified as moderate risk. In particular, older age needs to

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

be considered since the elderly are both at high individual risk and contribute significantly to population burden due to their relatively high numbers. Paradoxically, people in the shielded and moderate risk categories were less likely to be admitted to ICU following hospitalised for COVID-19 in spite of their poor prognosis. Patients over 70 years were particularly unlikely to be admitted to ICU. This is likely to be due to selective admission policies applied in order to avoid demand exceeding supply, as experienced by some other countries. This finding reinforces the importance of prevention in those with the worst prognosis. Comparison with existing literature Our finding of 26.41% percent of people satisfying the moderate risk criteria is consistent with the limited existing evidence. A previous study linking English primary and secondary care records on 3.9 million people reported that 20% of the population satisfied similar criteria<sup>20</sup>. Similarly, a study using data from the Global Burden of Diseases Study estimated that 22% of the global population are at increased risk of severe COVID-19 disease<sup>21</sup>. A USA study using data from the Behavioral Risk Factor Surveillance System reported that 45.4% of 444,649 adults had one or more of a longer list of morbidities that may be associated with higher risk from COVID-19<sup>22</sup>. Another USA study estimated that 14.2% of participants in the National Health Interview Survey had more than two-fold risk and 1.6% had more than 10fold risk<sup>23</sup>. The evidence on COVID-19 related complications among those people classified as high risk, and therefore advised to shield, has mainly come from case series, expert opinions,

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

unpublished reports. Evidence from case reports found higher COVID-19 related complications among organ transplant recipients <sup>24,25</sup>, patients receiving active cancer treatment (chemotherapy, radiotherapy or immunotherapy)<sup>26,27</sup>, and patients with haematological cancers<sup>28</sup>. Systematic review of case reports found higher COVID-19 complication risk among COPD patients, but the effect of COPD severity was not investigated<sup>29</sup>. Patients with cystic fibrosis and sickle cell disease were regarded as high risk for COVID-19 complications based on expert opinions<sup>30,31</sup>. While pregnant women with COVID-19 were found to have higher risk of poor maternal and perinatal outcomes<sup>32,33</sup>, outcomes were not investigated specifically for pregnant women with heart disease. There was no evidence found for higher COVID-19 related complications for patients on various immunosuppressants <sup>34</sup>. A large community study in England found strong association between severe asthma (hazard ratio 1.25) and COVID-19 related mortality but they did not investigate the risk of COVID-19 infection or hospitalisation<sup>9</sup>. In common with previous studies, we demonstrated that age was associated with one of the highest relative risks of death. Additionally, we showed the large extent to which age contributed to adverse outcomes at a population level with 79.14% of deaths attributable to age ≥70 years. The higher mortality in the elderly was mediated in part by their higher casefatality but they also had a higher incidence of infection, possibly due to transmission within care homes. Their lower likelihood of being admitted to ICU once hospitalised for COVID-19 may have contributed to their higher case-fatality. Previous studies have reported that men are at highest risk of from COVID-19.<sup>7</sup> Our study demonstrated that men are less likely than women to be tested for COVID-19, less likely have confirmed infection and slightly less likely to be hospitalised. They have comparable overall mortality from COVID-19, due to their lower incidence, but their case-fatality is significantly higher.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Strengths and Limitations This study adds to the existing evidence of the possible effectiveness of a shielding strategy which is currently limited to mathematical modelling of population effects based on assumptions <sup>11–19</sup>. Ours was a large-scale, unselected general population study. The data cover a period when shielding was in place. Linkage of primary care, laboratory, hospital and death data enabled us to examine a range of COVID-19 outcomes and study a range of exposure variables including the overall risk categories and their individual criteria. The datasets were linked using exact, rather than probabilistic, matching. We were able to adjust for potential sociodemographic confounders. The exposure data were collected prior to the outcomes occurring avoiding potential reverse causation and recall or recording bias. We did not have data on potential lifestyle confounding factors such as smoking and obesity, or ethnicity. We did not analyse multimorbidity or other potential risk factors not currently included in the high or moderate risk categories as the aim was to evaluate the current strategy. The shielding and moderate-risk criteria were correct at the time of extracting data but may be revised over time. Implications of findings Our findings suggest that our attempts to shield those at highest risk have not been as successful as hoped, with those advised to shield experiencing higher rates of infection and death. ICU provision has been successfully protected but via systematic exclusion of those with worse prognosis, rather than prevention of infection in those highest at risk. For shielding to be effective as a population level strategy, the current criteria would need to be

expanded since three-quarters of deaths were associated with moderate risk criteria for which shielding has not hitherto been recommended. In our study, more than one-quarter of the general population would have needed to be effectively shielded to prevent over 80% of deaths. Since this is unlikely to be acceptable at a time when governments are under pressure to ease lock-down restrictions, shielding is probably best viewed as an individual-level intervention to be used alongside other population-wide interventions such as physical distancing, face coverings and hand hygiene.

Availability of data and materials

- 2 The dataset supporting the conclusions of this article is available in the Glasgow Safe Haven
- 3 (https://www.nhsggc.org.uk/about-us/professional-support-sites/safe-haven/services/).

## 5 Acknowledgements

1

4

10

13

14

20

21

- We are extremely grateful to the following for their support and hard work in extracting and
- 7 linking the datasets and providing access to them: Charlie Mayor (Data Safe Haven
- 8 Manager), Alison Hamilton (Safe Haven Project Manager), Jonathan Todd (Head of
- 9 Information Management), Imran Sadat (Data Manager) and Neil Hillen (Data Analyst).

## 11 **Funding**

12 No external funding sources.

## **Conflicts of interest**

- 15 All authors have completed the ICMJE uniform disclosure form at
- 16 www.icmje.org/coi\_disclosure.pdf and declare: no support from any organisation for the
- submitted work; no financial relationships with any organisations that might have an interest
- in the submitted work in the previous three years; no other relationships or activities that
- 19 could appear to have influenced the submitted work.

## Contributors

- 22 FH and BJ contributed equally and are joint-first authors. BJ and JP conceptualised the study,
- 23 interpreted the data, and wrote the first draft of the manuscript. FH analysed the data and
- 24 wrote the first draft of the manuscript. All other authors interpreted the data and critically
- 25 revised the manuscript. All authors approved the final submitted version of the manuscript.

- BJ, FH, and JP serves as the guarantor of the manuscript and accepts full responsibility for
- 2 the work and/or the conduct of the study, had access to the data, and controlled the decision
- 3 to publish. The corresponding author attests that all listed authors meet authorship criteria
- 4 and that no others meeting the criteria have been omitted.

#### References

5

- Willan J, King AJ, Jeffery K, Bienz N. Challenges for NHS hospitals during covid-19 epidemic. *BMJ*. 2020;368. doi:10.1136/BMJ.M1117
- 8 2. ACAPS. #COVID19 A global joint response.
- 9 3. Swedish Civil Contingencies Agency (MSB). National ban on visiting elderly homes.
- 10 4. Radtke T, Haile SR, Dressel H, Benden C. Recommended shielding against COVID-
- 11 19 impacts physical activity levels in adults with cystic fibrosis. *J Cyst Fibros*.
- Published online 2020.
- 5. Kemp O, Horne GA, Soutar R. The psychological impact of COVID19 on a shielding high-risk cohort. *Scott Med J.* Published online 2020:0036933020951900.
- 15 6. Public Health England. Guidance on shielding and protecting people who are clinically extremely vulnerable from COVID-19.
- 17 7. Lipsitch M, Swerdlow DL, Finelli L. Defining the Epidemiology of Covid-19 —
- 18 Studies Needed. *N Engl J Med*. 2020;382(13):1194-1196.
- 19 doi:10.1056/NEJMp2002125
- 20 8. Lochlainn MN, Lee KA, Sudre CH, et al. Key predictors of attending hospital with
- 21 COVID19: An association study from the COVID Symptom Tracker App in 2,618,948 individuals. *medRxiv*. Published online April 2020:2020.04.25.20079251.
- 23 doi:10.1101/2020.04.25.20079251
- 24 9. The OpenSAFELY, Williamson E, Walker AJ, et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17
- 26 million adult NHS patients. *medRxiv*. Published online May
- 27 2020:2020.05.06.20092999. doi:10.1101/2020.05.06.20092999
- Wynants L, Van Calster B, Bonten MMJ, et al. Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal. *BMJ*.
- 30 2020;369:m1328. doi:10.1136/bmj.m1328
- 31 11. Vlas SJ de, Coffeng LE. A phased lift of control: a practical strategy to achieve herd immunity against Covid-19 at the country level. *medRxiv*. Published online 2020.
- 33 doi:10.1101/2020.03.29.20046011
- 34 12. Keeling MJ, Hill E, Gorsich E, et al. Predictions of COVID-19 dynamics in the UK:
- short-term forecasting and analysis of potential exit strategies. *medRxiv*. Published online 2020. doi:10.1101/2020.05.10.20083683
- 37 13. McKeigue PM, Colhoun HM. Evaluation of "stratify and shield" as a policy option for ending the COVID-19 lockdown in the UK. *medRxiv*. Published online 2020.
- 39 doi:10.1101/2020.04.25.20079913
- 40 14. Bunnik B Van, Woolhouse M, van Bunnik BAD. Segmentation and shielding of the most vulnerable members of the population as elements of an exit strategy from
- 42 COVID-19 lockdown. *medrxiv*. Published online 2020.
- 43 doi:10.1101/2020.05.04.20090597
- 44 15. Weitz JS, Beckett SJ, Coenen AR, et al. Intervention Serology and Interaction
- 45 Substitution: Modeling the Role of "Shield Immunity" in Reducing COVID-19

- 1 Epidemic Spread. medRxiv. Published online 2020. doi:10.1101/2020.04.01.20049767
- 2 16. Neufeld Z, Khataee H. Targeted adaptive isolation strategy for Covid-19 pandemic. 3 *medRxiv*. Published online 2020. doi:10.1101/2020.03.23.20041897
- 4 17. Acemoglu D, Chernozhukov V, Werning I, Whinston M. *Optimal Targeted Lockdowns in a Multi-Group SIR Model.*; 2020. doi:10.3386/w27102
- 6 18. Clark A, Jit M, Warren-Gash C, et al. Global, regional, and national estimates of the 7 population at increased risk of severe COVID-19 due to underlying health conditions 8 in 2020: a modelling study. *Lancet Glob Heal*. Published online 2020. 9 doi:10.1016/S2214-109X(20)30264-3
- 10 19. Davies NG, Kucharski AJ, Eggo RM, et al. Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study. *Lancet Public Heal*. Published online 2020. doi:10.1016/S2468-2667(20)30133-X
- 14 20. Banerjee A, Pasea L, Harris S, et al. Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study. *Lancet*. Published online 2020. doi:10.1016/s0140-6736(20)30854-0
- Clark A, Jit M, Warren-Gash C, et al. How many are at increased risk of severe
   COVID-19 disease? Rapid global, regional and national estimates for 2020. *medRxiv*.
   Published online 2020. doi:10.1101/2020.04.18.20064774
- 22. Adams ML, Katz DL, Grandpre J. Population based estimates of comorbidities
   affecting risk for complications from COVID-19 in the US. *medRxiv*. Published online
   23. 2020. doi:10.1101/2020.03.30.20043919
- 24 23. Jin J, Agarwala N, Kundu P, Chatterjee N. Estimating the Size of High-risk
   Populations for COVID-19 Mortality across 442 US Cities. Published online May
   26 2020. doi:10.1101/2020.05.27.20115170
- 24. Pereira M, Mohan S, Cohen D, et al. COVID-19 in Solid Organ Transplant Recipients:
   Initial Report From the US Epicenter. *Am J Transplant*. Published online 2020.
   doi:10.1111/AJT.15941
- 30 25. Fernández-Ruiz M, Andrés A, Loinaz C, et al. COVID-19 in Solid Organ Transplant
   31 Recipients: A Single-Center Case Series From Spain. *Am J Transplant*. Published
   32 online 2020. doi:10.1111/AJT.15929
- Zhang L, Zhu F, Xie L, et al. Clinical Characteristics of COVID-19-infected Cancer
   Patients: A Retrospective Case Study in Three Hospitals Within Wuhan, China. *Ann Oncol Off J Eur Soc Med Oncol*. Published online 2020.
   doi:10.1016/J.ANNONC.2020.03.296
- Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS COV-2: a multi-center study during the COVID-19 outbreak. *Cancer Discov*.
- 39 Published online April 2020. doi:10.1158/2159-8290.CD-20-0422
- 40 28. He W, Chen L, Chen L, et al. COVID-19 in persons with haematological cancers. 41 *Leukemia*. Published online April 2020:1-9. doi:10.1038/s41375-020-0836-7
- 42 29. Yang J, Zheng Y, Gou X, et al. Prevalence of Comorbidities and Its Effects in
   43 Coronavirus Disease 2019 Patients: A Systematic Review and Meta-Analysis. *Int J Infect Dis.* 2020;94. doi:10.1016/J.IJID.2020.03.017
- 45 30. Colombo C, Burgel P-R, Gartner S, et al. Impact of COVID-19 on people with cystic fibrosis. *Lancet Respir Med.* 2020;8(5):e35-e36. doi:10.1016/S2213-2600(20)30177-6
- 47 31. Rodriguez-Morales A, Cardona-Ospina J, Gutiérrez-Ocampo E, et al. Clinical,
- 48 Laboratory and Imaging Features of COVID-19: A Systematic Review and Meta-
- 49 Analysis. *Travel Med Infect Dis*. Published online 2020.
- 50 doi:10.1016/J.TMAID.2020.101623

- 1 32. Di Mascio D, Khalil A, Saccone G, et al. Outcome of Coronavirus Spectrum Infections
  2 (SARS, MERS, COVID 1 -19) During Pregnancy: A Systematic Review and Meta3 Analysis. *Am J Obstet Gynecol MFM*. Published online 2020.
  4 doi:10.1016/J.AJOGMF.2020.100107
- 5 33. Elshafeey F, Magdi R, Hindi N, et al. A Systematic Scoping Review of COVID-19 During Pregnancy and Childbirth. *Int J Gynaecol Obstet*. Published online 2020. doi:10.1002/IJGO.13182

11 12

Minotti C, Tirelli F, Barbieri E, Giaquinto C, D D. How Is Immunosuppressive Status
 Affecting Children and Adults in SARS-CoV-2 Infection? A Systematic Review. *J Infect*. 2020;S0163-4453. doi:10.1016/J.JINF.2020.04.026

**Table 1.** COVID-19 testing status by sociodemographic characteristics, risk category and risk criteria

	COVI		
	Not tested	Tested	
	N=1,299,206	N=15,865	
	n (%)	n (%)	P value
Age group (years)			< 0.0001
0-24	355,238 (99.49)	1,822 (0.51)	
25-44	410,408 (99.22)	3,247 (0.78)	
45-64	340,268 (98.65)	4,660 (1.35)	
≥65	193,292 (96.92)	6,136 (3.08)	
Sex			< 0.0001
Male	654,041 (99.01)	6,569 (0.99)	
Female	645,165 (98.58)	9,296 (1.42)	
Deprivation quintile			< 0.0001
1 (most deprived)	461,672 (98.67)	6,211 (1.33)	
2	230,402 (98.75)	2,921 (1.25)	
3	194,702 (98.90)	2,175 (1.10)	
4	173,456 (98.93)	1,883 (1.07)	
5 (most affluent)	238,974 (98.89)	2,675 (1.11)	
Risk category			< 0.0001
Low	928,397 (99.28)	6,767 (0.72)	
Moderate	340,473 (98.01)	6,901 (1.99)	
Shielded	30,336 (93.25)	2,197 (6.75)	
Moderate risk criteria			
Chronic respiratory disease	149,325 (98.33)	2,540 (1.67)	< 0.0001
Heart disease	46,728 (96.21)	1,843 (3.79)	< 0.0001
Hypertension	156,286 (97.55)	3,929 (2.45)	< 0.0001
Diabetes	62,482 (97.09)	1,876 (2.91)	< 0.0001
Weakened immune system	1,140 (95.40)	55 (4.60)	< 0.0001
≥70 years of age	134,305 (96.23)	5,263 (3.77)	< 0.0001
Shielded criteria			
Severe respiratory disease	17,146 (94.48)	1,001 (5.52)	< 0.0001
Specific cancers	2,075 (83.30)	416 (16.70)	< 0.0001
Pregnant with severe heart disease	<5	0	-
Immunosuppressive therapy	5,028 (94.00)	321 (6.00)	< 0.0001
Solid organ transplant	1,149 (92.29)	96 (7.71)	< 0.0001
Rare diseases and inborn errors of metabolism	1,623 (91.95)	142 (8.05)	< 0.0001
Renal dialysis	6,216 (91.94)	545 (8.06)	< 0.0001

6 N number

5

1 2

3 4

Table 2. Crude, population-level COVID-19 outcomes by sociodemographic characteristics, risk category and risk criteria

	Confirmed COVID-19 infection		COVID-1	COVID-19 hospitalisation			COVID-19 ICU admission			COVID-19 mortality		
	Negative test/ Not tested	Positive test	P-value	Not admitted	Admitted	P-value	Not admitted	Admitted	P-value	Alive	Dead	P-value
	N=1,311,723 n (%)	N=3,348 n (%)		N=1,313,410 n (%)	N=1,661 n (%)		N=1,314,949 n (%)	N=122 n (%)		N=1,314,044 n (%)	N=1,027 n (%)	_
Age group (years)			< 0.0001			< 0.0001			0.0005			<0.0001
0-24	356,944 (99.97)	116 (0.03)		357,041 (99.99)	19 (0.01)		357,060 (100.00)	0		357,060 (100.00)	0(0.00)	
25-44	413,123 (99.87)	532 (0.13)		413,532 (99.97)	123 (0.03)		413,643 (100.00)	12 (0.00)		413,647 (100.00)	8 (0.00)	lac
45-64	343,856 (99.69)	1,072 (0.31)		344,409 (99.85)	519 (0.15)		344,846 (99.98)	82 (0.02)		344,838 (99.97)	90 (0.03)	ē
≥65	197,800 (99.18)	1,628 (0.82)		198,428 (99.50)	1,000 (0.50)		199,400 (99.99)	28 (0.01)		198,499 (99.53)	929 (0.47)	SVE
Sex												made available
Male	659,203 (99.79)	1,407 (0.21)	< 0.0001	659,781 (99.87)	829 (0.13)	0.81	660,525 (99.99)	85 (0.01)	< 0.0001	660,092 (99.92)	518 (0.08)	0.92
Female	652,250 (99.70)	1,941 (0.30)		659,369 (99.87)	832 (0.13)		660,908 (99.99)	37 (0.01)		653,952 (99.92)	509 (0.08)	e _
Deprivation quintile			0.0002			< 0.0001			0.18			<0.00012
1 (most deprived)	466,582 (99.72)	1,301 (0.28)		467,146 (99.84)	737 (0.16)		467,832 (99.99)	51 (0.01)		467,442 (99.91)	441 (0.09)	er
2	232,710 (99.74)	613 (0.26)		233,041 (99.88)	282 (0.12)		233,302 (99.99)	21 (0.01)		233,181 (99.94)	142 (0.06)	മ
3	196,416 (99.77)	461 (0.23)		196,651 (99.89)	226 (0.11)		196,854 (99.99)	23 (0.01)		196,724 (99.92)	153 (0.08)	8
4	174,939 (99.77)	400 (0.23)		175,143 (99.89)	196 (0.11)		175,329 (99.99)	10 (0.01)		175,209 (99.93)	130 (0.07)	ù
5 (most affluent)	241,076 (99.76)	573 (0.24)		241,429 (99.91)	220 (0.09)		241,632 (99.99)	17 (0.01)		241,488 (99.93)	161 (0.07)	Ť
Risk category	,,	,	< 0.0001	, . ( ,	( , , , ,	< 0.0001	,	,	< 0.0001	,,	( , , , ,	<0.00010-ND 4
Low	933,977 (99.87)	1,187 (0.13)		934,768 (99.96)	396 (0.04)		935,099 (99.99)	65 (0.01)		935,081 (99.99)	83 (0.01)	7
Moderate	345,552 (99.48)	1,822 (0.52)		346,372 (99.71)	1,002 (0.29)		347,325 (99.99)	49 (0.01)		346,572 (99.77)	802 (0.23)	ō
Shielded	32,194 (98.96)	339 (1.04)		32,270 (99.19)	263 (0.81)		32,525 (99.98)	8 (0.02)		32,391 (99.56)	142 (0.44)	4.0
Moderate risk criteria	32,171 (70.70)	337 (1.01)		32,270 (>>.1>)	203 (0.01)		32,323 (77.70)	0 (0.02)		32,371 (77.30)	112 (0.11)	2
Chronic respiratory disease	151,414 (99.70)	451 (0.30)	0.0005	151,618 (99.84)	247 (0.16)	< 0.0001	151,853 (99.99)	12 (0.01)	0.65	151,812 (99.97)	53 (0.03)	<0.0001
Heart disease	48,176 (99.19)	395 (0.81)	< 0.0003	48,325 (99.49)	246 (0.51)	< 0.0001	48,564 (99.99)	7 (0.01)	0.34	48,456 (99.76)	115 (0.24)	<0.0001
Hypertension	159,267 (99.41)	948 (0.59)	< 0.0001	159,670 (99.66)	545 (0.34)	< 0.0001	160,189 (99.98)	26 (0.02)	0.003	159,991 (99.86)	224 (0.14)	<0.0001
Diabetes	63,903 (99.29)	455 (0.71)	< 0.0001	64,063 (99.54)	295 (0.46)	< 0.0001	64,335 (99.96)	23 (0.04)	< 0.0001	64,263 (99.85)	95 (0.15)	< 0.0001
Weakened immune system	1,183 (99.00)	12 (1.00)	< 0.0001	1,185 (99.16)	10 (0.84)	< 0.0001	1,195 (100.00)	0 (0.00)	-	1,189 (99.50)	6 (0.50)	< 0.0001
≥70 years of age	138,115 (98.96)	1,453 (1.04)	< 0.0001	138,701 (99.38)	867 (0.62)	< 0.0001	139,560 (99.99)	8 (0.01)	0.19	138,690 (99.37)	878 (0.63)	< 0.0001
Shielded group		, ,		(	,			,			,	SC
Severe respiratory disease	17.981 (99.09)	166 (0.91)	< 0.0001	18,012 (99.26)	135 (0.74)	< 0.0001	18.146 (99.99)	<5	_	18.059 (99.52)	88 (0.48)	<0.0001.
Specific cancers	2,452 (98.43)	39 (1.57)	< 0.0001	2,462 (98.84)	29 (1.16)	< 0.0001	2,491 (100.00)	0	-	2,475 (99.36)	16 (0.64)	< 0.0001
Pregnant, severe heart disease	<5	0	-	<5	0	-	<5	0	-	<5	0(0.00)	-
Immunosuppressive therapy	5,285 (98.80)	64 (1.20)	< 0.0001	5,299 (99.07)	50 (0.93)	< 0.0001	5,346 (99.94)	<5	-	5,324 (99.53)	25 (0.47)	< 0.0001
Solid organ transplant	1,228 (98.63)	17 (1.37)	< 0.0001	1,230 (98.80)	15 (1.20)	< 0.0001	1,244 (99.92)	<5	-	1,238 (99.44)	7 (0.56)	< 0.0001
Rare diseases and IEM	1,729 (97.96)	36 (2.04)	< 0.0001	1,741 (98.64)	24 (1.36)	< 0.0001	1,764 (99.94)	<5	-	1,744 (98.81)	21 (1.19)	< 0.0001
Renal dialysis	6,684 (98.86)	77 (1.14)	< 0.0001	6,704 (99.16)	57 (0.84)	< 0.0001	6,758 (99.96)	<5	-	6,749 (99.82)	12 (0.18)	0.007

N number; IEM inborn errors of metabolism

Table 3. Associations\* between risk categories and risk criteria and population-level COVID-19 outcomes

	Confirmed COVID-19 infection		COVID-19 hospitalisation		COVID-19 ICU a	dmission	COVID-19 mortality		
	RR (95% CI)	P-value	RR (95% CI)	P-value	RR (95% CI)	P-value	RR (95% CI)	P-value	
Low	1 (Reference)		1 (Reference)		1 (Reference)		1 (Reference)		
Moderate									
Overall	4.11 (3.82-4.42)	< 0.0001	6.82 (6.07-7.66)	< 0.0001	2.06 (1.42-2.98)	0.0001	26.10 (20.89-32.60)	0.0001	
Chronic respiratory disease	2.31 (2.07-2.57)	< 0.0001	3.80 (3.24-4.45)	< 0.0001	1.15 (0.62-2.14)	0.65	3.92 (2.80-5.50)	0.0001	
Heart disease	6.54 (5.84-7.33)	< 0.0001	11.75 (10.02-13.77)	< 0.0001	1.92 (0.88-4.19)	0.1	26.30 (19.92-34.74)	0.0001	
Hypertension	4.61 (4.23-5.02)	< 0.0001	8.09 (7.11-9.20)	< 0.0001	2.44 (1.55-3.84)	0.0001	15.87 (12.38-20.35)	0.0001	
Diabetes	5.61 (5.03-6.24)	< 0.0001	10.6 (9.12-12.32)	< 0.0001	4.89 (3.04-7.88)	< 0.0001	16.42 (12.29-21.93)	0.0001	
Weakened immune system	7.81 (4.44-13.76)	< 0.0001	19.82 (10.60-37.07)	< 0.0001	-	-	56.85 (25.14-128.55)	0.0001	
≥70 years of age	8.10 (7.50-8.74)	< 0.0001	15.12 (13.42-17.03)	< 0.0001	0.90 (0.43-1.86)	0.77	73.85 (59.45-91.75)	0.0001	
Shielded									
Overall	7.91 (7.01-8.92)	< 0.0001	18.47 (15.79-21.59)	< 0.0001	3.67 (1.76-7.65)	0.0005	48.64 (37.23-63.56)	0.0001	
Severe respiratory disease	6.82 (5.79-8.02)	< 0.0001	16.59 (13.63-20.19)	< 0.0001	-	-	53.52 (39.77-72.02)	0.0001	
Specific cancers	12.16 (8.85-16.70)	< 0.0001	27.49 (18.87-40.04)	< 0.0001	-	-	72.55 (42.83-122.88)	0.0001	
Immunosuppressive therapy	9.28 (7.23-11.92)	< 0.0001	22.08 (16.47-29.61)	< 0.0001	-	-	52.86 (34.03-82.11)	0.0001	
Solid organ transplant	10.98 (6.82-17.67)	< 0.0001	28.18 (16.85-47.12)	< 0.0001	-	-	63.06 (29.50-134.80)	0.0001	
Rare diseases and IEM	15.95 (11.47-22.18)	< 0.0001	31.77 (21.06-47.91)	< 0.0001	-	-	133.80 (83.50-214.41)	0.0001	
Renal dialysis	8.76 (6.97-11.02)	< 0.0001	19.66 (14.90-25.94)	< 0.0001	-	-	20.03 (11.04-36.36)	0.0001	

\*adjusted for sex and deprivation quintile RR relative risk; CI confidence interval; IEM inborn errors of metabolism

Table 4. Crude COVID-19 outcomes among confirmed cases by sociodemographic characteristics, risk category and risk criteria

	COVID-19 hospitalisation N=3,348 <sup>†</sup>			COVID-19 ICU admission N=3,348 <sup>†</sup>			COVID-19 case-fatality N=3,846 <sup>‡</sup>		
	Not admitted N=1,687 n (%)	Admitted N=1,661 n (%)	P-value	Not admitted N=3,226 n (%)	Admitted N=122 n (%)	P-value	Alive N=2,819 n (%)	Dead N=1,027 n (%)	P-value
Age group (years)			< 0.0001			< 0.0001			< 0.0001
0-24	97 (83.62)	19 (16.38)		116 (100.00)	0		116 (100.00)	0(0.00)	
25-44	410 (76.92)	123 (23.08)		520 (97.74)	12 (2.26)		526 (98.50)	8 (1.50)	
45-64	553 (51.59)	519 (48.41)		990 (92.35)	82 (7.65)		1,003 (91.77)	90 (8.23)	
≥65	630 (38.65)	1,000 (61.35)		1,600 (98.28)	28 (1.72)		1,174 (55.83)	929 (44.17)	
Sex		, (,		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,		, . (,		< 0.0001
Male	579 (41.12)	829 (58.88)	< 0.0001	1,322 (93.96)	85 (6.04)	< 0.0001	1,105 (68.08)	518 (31.92)	
Female	1,108 (57.11)	832 (42.89)		1,904 (98.09)	37 (1.91)		1,717 (77.10)	509 (22.90)	
Deprivation Quintile	1,200 (0,122)	00=(1=10)	< 0.0001	2,201 (20102)	- (-1, -)	0.29	-, ()		0.0004
1 (most deprived)	566 (43.44)	737 (56.56)		1,250 (96.08)	51 (3.92)		1,046 (70.34)	441 (29.66)	
2	332 (54.07)	282 (45.93)		592 (96.57)	21 (3.43)		531 (78.90)	142 (21.10)	
3	235 (50.98)	226 (49.02)		438 (95.01)	23 (4.99)		394 (72.03)	153 (27.97)	
4	204 (51.00)	196 (49.00)		390 (97.50)	10 (2.50)		341 (72.40)	130 (27.60)	
5 (most affluent)	353 (61.61)	220 (38.39)		556 (97.03)	17 (2.97)		507 (75.90)	161 (24.10)	
Risk category	(01101)	(e a.e., )	< 0.0001	(5.130)	(=)	0.0001	( )	()	< 0.0001
Low	792 (66.67)	396 (33.33)	10.0001	1,122 (94.52)	65 (5.48)	0.0001	1,128 (93.15)	83 (6.85)	10.0001
Moderate	820 (45.01)	1,002 (54.99)		1,773 (97.31)	49 (2.69)		1,448 (64.36)	802 (35.64)	
Shielded	78 (22.87)	263 (77.13)		331 (97.64)	8 (2.36)		243 (63.12)	142 (36.88)	
Moderate risk criteria	76 (22.67)	203 (77.13)		331 (77.04)	0 (2.50)		243 (03.12)	142 (30.00)	
Chronic respiratory disease	205 (45.35)	247 (54.65)	0.02	439 (97.34)	12 (2.66)	0.29	420 (88.79)	53 (11.21)	< 0.0001
Heart disease	149 (37.72)	246 (62.28)	< 0.0001	388 (98.23)	7 (1.77)	0.29	330 (74.16)	115 (25.84)	0.7
Hypertension	404 (42.57)	545 (57.43)	< 0.0001	922 (97.26)	26 (2.74)	0.10	836 (78.87)	224 (21.13)	< 0.0001
Diabetes	161 (35.31)	295 (64.69)	< 0.0001	432 (94.95)	23 (5.05)	0.11	398 (80.73)	95 (19.27)	< 0.0001
Weakened immune system	2 (16.67)	10 (83.33)	0.04	12 (100.00)	0	-	6 (50.00)	6 (50.00)	0.13
≥70 years of age	587 (40.37)	867 (59.63)	< 0.0001	1,445 (99.45)	8 (0.55)	< 0.0001	1,035 (54.10)	878 (45.90)	< 0.0001
Shielding criteria		(		, , , , ,	( ( ) ( )		, ( ,		
Severe respiratory disease	33 (19.64)	135 (80.36)	< 0.0001	165 (99.40)	<5	_	111 (55.78)	88 (44.22)	< 0.0001
Specific cancers	10 (25.64)	29 (74.36)	0.003	39 (100.00)	0	-	27 (62.79)	16 (37.21)	0.16
Pregnant, severe heart disease	/	` _	=	-	=	-	- ′	- '	-
Immunosuppressive therapy	14 (21.88)	50 (78.12)	< 0.0001	61 (95.31)	<5	-	42 (62.69)	25 (37.31)	0.07
Solid organ transplant	2 (11.76)	15 (88.24)	0.003	16 (94.12)	<5	-	11 (61.11)	7 (38.89)	0.37
Rare diseases and IEM	12 (33.33)	24 (66.67)	0.06	35 (97.22)	<5	-	23 (52.27)	21 (47.73)	0.003
Renal dialysis	20 (25.97)	57 (74.03)	< 0.0001	74 (96.10)	<5	-	66 (84.62)	12 (15.38)	0.03

<sup>†</sup>laboratory-confirmed (test-positive) COVID-19 cases †clinically-confirmed (test-positive or COVID-19 on death certificate) COVID-19 cases N number; IEM inborn errors of metabolism

Table 5. Associations\* between risk categories and risk criteria and COVID-19 outcomes among confirmed cases

	COVID-19 hospit N=3,348		COVID-19 ICU a N=3,348		COVID-19 case-fatality N=3,846 <sup>‡</sup>		
	RR (95% CI)	P-value	RR (95% CI)	P-value	RR (95% CI)	P-value	
Low	1 (Reference)		1 (Reference)		1 (Reference)		
Moderate							
Overall	1.33 (1.22-1.46)	< 0.0001	0.38 (0.26-0.55)	< 0.0001	5.13 (4.24-6.21)	< 0.0001	
Chronic respiratory disease	1.56 (1.39-1.76)	< 0.0001	0.46 (0.25-0.86)	0.02	1.63 (1.22-2.18)	0.001	
Heart disease	1.60 (1.42-1.81)	< 0.0001	0.24 (0.11-0.53)	0.0004	3.57 (2.81-4.54)	< 0.0001	
Hypertension	1.54 (1.40-1.70)	< 0.0001	0.44 (0.28-0.69)	0.0004	3.06 (2.48-3.79)	< 0.0001	
Diabetes	1.71 (1.52-1.91)	< 0.0001	0.72 (0.45-1.18)	0.19	2.65 (2.06-3.40)	< 0.0001	
Weakened immune system	2.43 (1.51-3.89)	0.0002	-	-	7.14 (3.54-14.39)	< 0.0001	
≥70 years of age	1.37 (1.25-1.49)	< 0.0001	0.07 (0.04-0.15)	< 0.0001	6.59 (5.46-7.96)	< 0.0001	
Shielded							
Overall	1.96 (1.74-2.21)	< 0.0001	0.33 (0.16-0.70)	0.004	5.19 (4.12-6.53)	< 0.0001	
Severe respiratory disease	1.94 (1.67-2.25)	< 0.0001	-	-	6.23 (4.83-8.03)	< 0.0001	
Specific cancers	1.89 (1.42-2.51)	< 0.0001	-	-	5.04 (3.21-7.93)	< 0.0001	
Immunosuppressive therapy	2.17 (1.74-2.71)	< 0.0001	-	-	5.19 (3.56-7.58)	< 0.0001	
Solid organ transplant	2.33 (1.58-3.44)	< 0.0001	-	-	5.24 (2.73-10.07)	< 0.0001	
Rare diseases and IEM	1.50 (1.10-2.05)	0.01	-	-	6.64 (4.42-9.96)	< 0.0001	
Renal dialysis	2.15 (1.74-2.65)	< 0.0001	-	-	2.20 (1.32-3.66)	0.003	

<sup>\*</sup>adjusted for sex and deprivation quintile

†laboratory-confirmed (test-positive) COVID-19 cases

‡clinically-confirmed (test-positive or COVID-19 on death certificate) COVID-19 cases

N number; RR relative risk; CI confidence interval; IEM inborn errors of metabolism